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Abstract
Nucleolus is a dynamic structure that controls biogenesis of ribosomal RNA and senses cellular stresses. Nucleolus contains a
number of proteins including ribosomal proteins that conduct cellular stresses to downstream signaling such as p53
pathway. Recently, it has been reported that modification by a ubiquitin-like molecule, Nedd8, regulates subnuclear
localization of ribosomal protein L11. Most of L11 is normally localized and neddylated in nucleolus. However, cellular stress
triggers deneddylation and redistribution of L11, and subsequent activation of p53. Although Nedd8 modification is
thought to be important for L11 localization, the mechanism of how neddylation of L11 is regulated remains largely
unknown. Here, we show that Myeloma overexpressed 2 (Myeov2) controls L11 localization through down-regulation of
Nedd8 modification. Expression of Myeov2 reduced neddylation of proteins including L11. We also found that Myeov2
associates with L11 and withholds L11 in nucleoplasm. Although Myeov2 interacted with a Nedd8 deconjugation enzyme
COP9 signalosome, L11 deneddylation was mediated by another deneddylase Nedp1, independently of Myeov2. Finally,
p53 transcriptional activity is upregulated by Myeov2 expression. These data demonstrate that Myeov2 hampers L11
neddylation through their interactions and confines L11 to nucleoplasm to modulate nucleolar integrity. Our findings
provide a novel link between oncogenic stress and p53 pathway and may shed light on the protective mechanism against
cancer.
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Introduction
Nucleolus is a non-membrane organelle composed of ribosomal
DNA and proteins. The major functions of nucleolus are synthesis
of ribosomal RNA (rRNA) and ribosomal subunit assembly. In
addition, nucleolus acts as a sensor of cellular stress response and
transmits signals to stress response pathways [1,2]. Exposure to a
variety of stresses such as DNA damage, heat shock, and inhibition
of DNA and RNA synthesis causes nucleolus disruption, leading to
activation of p53, which is the primary mediator of the stress
response [1,2]. Recent studies have identified a number of
nucleolar proteins such as ribosomal proteins, INK4a/ARF
(ARF), PICT1 and Nucleophosmin (NPM) [3,4,5], those are
crucial for the regulation of stress-induced activation of p53
pathway. For instance, subsets of ribosomal proteins are implicat-
ed in stress-induced p53 activation and one of well-characterized
proteins is L11 [6,7,8,9,10,11,12,13]. L11 is localized in nucleolus
under normal condition and supports nuclear integrity. On the
other hand, L11 is released to nucleoplasm upon nucleolar stress,
and binds to and inhibits Mdm2, the major p53 ubiquitin ligase,
leading to p53 activation [6,7] or recruitment of co-activator
p300/CBP to p53 promoter site [14]. Thus, L11 is one of the key
mediators that link nucleolar stress to p53 pathway. In addition,
ARF, a tumor suppressor protein, is normally localized in
nucleolus through interaction with NPM [15]. However, in
response to nucleolar stress, ARF redistributes to nucleoplasm
and interacts with p53 ubiquitin ligase, Mdm2, followed by
suppression of Mdm2 activity [4,16,17,18,19]. Consequently, p53
accumulates in nucleus and induces target gene expression.
Furthermore, it has recently been reported that another nucleolar
protein, PICT1 interacts with L11, and confines L11 to nucleolus.
However, PICT1 releases L11 into nucleoplasm following
nucleolar stress, leading to suppression of Mdm2 [5]. Taken
together, nucleolus acts as a central hub for tuning cellular stress
response, and nucleolar stress alters properties of proteins in
nucleolus and conducts signaling to p53 pathway.
It has been demonstrated that several nucleolar stress-related
proteins including L11 are modified by a ubiquitin-like protein,
Nedd8. A number of ribosomal proteins are usually neddylated
in vivo [20]. This neddylation plays an important role in
regulating the stability and subcellular localization of these
proteins. In response to nucleolar stress, L11 is deneddylated by
Nedd8 deconjugation enzyme, Nedp1/Den1/SENP8, and trans-
locates from nucleolus to nucleoplasm, leading to an induction of
p53 activity [21]. On the other hand, Mdm2 has also been
reported to be a target of Nedd8 modification by itself [22]. Mdm2
possesses an E3 ligase activity of not only ubiquitin but also
Nedd8. Mdm2 is autoneddylated to prevent degradation in resting
state and is capable of both ubiquitination and neddylation of p53.
However, treatment with chemotherapeutic agent such as
doxorubicin promotes Nedd8 deconjugation from Mdm2, desta-
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bilizes and degrades Mdm2, followed by accumulation of p53
[23]. Thus, these observations suggest that Nedd8 pathway is
crucial for the regulation of stress response. However despite the
importance of Nedd8 pathway, the mechanisms by which stresses
control Nedd8 modification are not fully understood.
Multiple myeloma is a plasma cell cancer. Plasma cells
differentiate from B cells in bone marrow, and produce a huge
number of specific antibodies [24,25]. Plasma cells have unique
‘‘wheel-spoke’’ like chromatin structure and their nucleolus cannot
be normally observed. However, once plasma cells transform into
plasmacytoma, enlarged nucleoli appear in nucleus [26,27].
Therefore, abnormal nucleolus is considered to be a pathological
feature in multiple myeloma. So far, it has been reported that
several proteins are associated with multiple myeloma [24,25].
Among them, Myeloma overexpressed 2 (Myeov2) was initially
reported as a 57 amino acid protein [28], but was later discovered
to be a 252 amino acid protein (www.ensembl.org). Myeov2 is
evolutionarily conserved from plant to human, and thought to
have similar functions among different species. Given that Myeov2
is expressed abnormally in myeloma cells, expression level should
be tightly regulated to maintain normal state and it is likely that
Myeov2 expression is associated with the onset of multiple
myeloma. However, it is largely unknown how Meyov2 is
regulated.
In this study, we found that Myeov2 regulates L11 subnucleolar
localization and consequently Nedd8 modification. Overexpres-
sion of Myeov2 led to a decrease of neddylated L11 and high
proportion of nucleoplasmic L11. Intriguingly, Myeov2 interacted
with COP9 signalosome, a Nedd8 deconjugation enzyme,
although the interaction was not essential for Myeov2-mediated
L11 deneddylation. Because expression level of Myeov2 is
associated with multiple myeloma, our findings suggest that
Myeov2 is a primary mediator that regulates nucleolus integrity
and stress response pathway.
Results
Myeov2 Associates with COP9 Signalosome
Myeov2 is overexpressed in myeloma cells and appears to be
associated with the plasmacytes proliferation and transformation.
Although expression level of Myeov2 is considered to be important
for the tumorigenesis of plasma cells, little is known about the
function of Myeov2. To investigate this, we searched for target
proteins that interact with Myeov2 in HEK293 cells. We identified
18 proteins that associate with Myeov2 at least three times of four
experiments (score$3). Surprisingly, all subunits of COP9
signalosome were co-precipitated with Flag-Myeov2 (Fig. 1A).
COP9 signalosome is a protein complex composed of 8 subunits
(CSN1 to CSN8) that possesses deneddylation activity toward
Cullin family proteins, which are components of Cullin-RING
ubiquitin ligase (CRLs) [29,30]. Given that deconjugating activity
of COP9 signalosome is crucial for CRLs-dependent cellular
proliferation and viability, we hypothesized that COP9 signalo-
some and CRLs are functional targets of Myeov2. To verify those
interactions by immunoprecipitation experiment, we co-transfect-
ed HEK293T cells with HA-Myeov2 and Flag-CSN5, a catalytic
subunit of COP9 signalosome. Immunoprecipitation of Flag-
CSN5 resulted in co-immunoprecipitation of HA-Myeov2
(Fig. 1B). Reciprocal immnoprecipitation experiment by trans-
fecting the cells with Flag-Myeov2, revealed the association of
Flag-Myeov2 with endogenous CSN5, indicating that Myeov2
associates with CSN5 (Fig. 1C). To further explore the domain
important for the interaction, we made deletion mutants of
Myeov2 and introduced these constructs into HEK293T cells
(Fig. 1D). We found that a FD region, which is a phenylalanine-
aspartic acid rich domain and well conserved among different
species, is essential for the binding with CSN5. Furthermore, FD
region was also important for the association with Cullin family
proteins (Fig. 1E). Taken together, these data imply that COP9
signalosome is a putative target of Myeov2.
Expression of Myeov2 maintains L11 in a Lower
Neddylation Level
COP9 signalosome mediates the deneddylation of Cullin family
proteins and regulate CRLs activity; however, the mechanisms of
how COP9 signalosome is activated are not well understood.
Because our data imply that Myeov2 could be another component
of COP9 signalosome, we asked whether Myeov2 mediates
deneddylating activity. Unexpectedly, expression of Flag-Myeov2
did not change the neddylation status of Cul1, a cullin family
protein (Fig. 2A). Thus, these data suggest that Myeov2 does not
enhance deneddylation activity of COP9 signalosome at least in
this system. Meanwhile, we found that expression of Myeov2 led to
a global decrease of neddylated protein under the same
experimental condition (Fig. 2A), and dominant negative CSN5
does not suppress this effect (data not shown). In addition,
Myeov2DFD, which cannot interact with COP9 signalosome, also
reduced the proportion of neddylated protein. However, as
neddylation status was examined by ectopic expression of HA-
Nedd8, it was possible that variability in transfection efficiency
among each sample have affected the proportion of neddylated
proteins. To avoid this possibility, we detected endogenous
neddylated proteins using anti-Nedd8 antiserum (See Fig.S1 for
the characterization of antiserum). The Nedd8 antiserum recog-
nized a number of endogenous neddylated proteins (Fig. S1).
When film exposure time was shortened, bands of around
30,40 kDa proteins were still detected even though most bands
became undetectable (Fig. 2B). Interestingly, the expression of
both Myeov2 and Myeov2DFD significantly decreased these
bands, especially a band of ,35 kDa protein (Fig. 2B). Therefore,
we speculated that these proteins, especially ,35 kDa protein, are
potent target(s) of Myeov2. Several proteins including a subset of
ribosomal proteins have been reported to be neddylated so far and
the molecular weights of those ribosomal proteins are around
15,30 kDa [20]. Among several ribosomal proteins that are
neddylated, we focused on L11, whose molecular weight is
estimated to be 35kDa upon neddylation. L11 is modified by
Nedd8 at multiple sites, and plays pivotal roles in regulation of p53
pathway. Thus we hypothesized that ,35 kDa protein is L11
conjugated by monomeric or multimeric Nedd8. To examine this,
we transfected cells with His-Nedd8 and Myc-L11, and precipi-
tated neddylated proteins using Talon metal affinity beads under
denatured condition. As expected, precipitated Myc-L11 was
covalently conjugated with His-Nedd8 and expression of Myeov2
reduced the amount of precipitated L11. In addition,
Myeov2DFD, which cannot associate with COP9 signalosome,
also reduced the amount of precipitated L11 similar to Myeov2
(Fig. 2C).
We next investigated the molecular mechanisms of how
expression of Myeov2 causes a decrease of neddylation status of
L11. To explore this question, we focused on another deneddylat-
ing enzyme, Nedp1, which possesses a deneddylation activity for a
broad range of proteins in cells [31]. We transfected cells with His-
Nedd8, HA-Nedp1 and HA-CSN5 as indicated. When His-Nedd8
was precipitated using Talon metal affinity beads, multiple
neddylated proteins were co-precipitated. Co-expression of Nedp1
clearly reduced this multiple bands, while that of CSN5 had no
effect, suggesting that Nedp1, but not COP9 signalosome, is a
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primary deneddylating enzyme for L11 (Fig. 2D). We next
investigated whether Myeov2 enhances Nedp1 activity. Because
Nedp1 has a strong enzymatic activity in our system (Fig. 2D), we
used lower amount of Nedp1 construct to detect the effect of
Nedp1 activity in the presence or absence of Myeov2. Co-
expression of Myeov2 did not further enhance Nedp1 activity
(Fig. 2E), suggesting that Myeov2 has little effect on the regulation
of Nedp1 activity. We also examined whether Myeov2 is necessary
for the reduction of L11 neddylation level. To do this, we
developed short hairpin RNAs that target Myeov2 (shMyeov2).
Knockdown of Myeov2 has little effect on neddylation level of
L11, implying that Myeov2 is not necessary for the inhibition of
L11 neddylation (Fig.S2). Finally, Myeov2 did not interact with
Nedp1 (Fig. S3), supporting our data that Myeov2 is not involved
Figure 1. Myeov2 associates with COP9 signalosome. (A) Protein identified by mass spectrometry of Myeov2 immunoprecipitants. The colored
squares show how often a protein was identified in multiple experiments. (B) Co-immunoprecipitation of HA-Myeov2 and Flag-CSN5 in HEK293T
cells. Cell lysates were immunoprecipitated with anti-Flag antibody and analyzed using Flag and HA antibodies. (C) Co-immunoprecipitation of Flag-
Myeov2 and endogenous CSN5 in HEK293T cells. Cell lysates were immunoprecipitated with anti-Flag antibody and analyzed using Flag and CSN5
antibodies. (D) Schematic structure of Myeov2 deletion mutants. (E) Co-immunoprecipitation of CSN5, Cul1, and Cul3 with Flag-Myeov2 in HEK293
cells. Cell lysates were immunoprecipitated with anti-Flag antibody and analyzed using indicated antibodies.
doi:10.1371/journal.pone.0065285.g001
Myeov2 Regulates L11 Subnuclear Localization
PLOS ONE | www.plosone.org 3 June 2013 | Volume 8 | Issue 6 | e65285
Myeov2 Regulates L11 Subnuclear Localization
PLOS ONE | www.plosone.org 4 June 2013 | Volume 8 | Issue 6 | e65285
in Nedp1-mediated L11 deneddylation, and this may propose a
potential mechanism by which Myeov2 leads to a decrease of
neddylated L11 through suppression of neddylation and contrib-
utes to maintain a small proportion of neddylated L11 in cells.
Myeov2 Alters L11 Subnuclear Localization without
Nucleolar Disruption
L11 is usually localized in nucleolus and is relocated to
nucleoplasm in response to nucleolar stress, followed by activation
of p53 pathway. In addition, Nedd8 pathway is thought to be
important for subnuclear localization of L11 [21]. We thus
examined if Myeov2 regulates L11 subnuclear localization. Most
of L11 were localized in nucleolus; however, expression of Myeov2
increased a population of nucleoplasmic L11. Myeov2DFD also
confined L11 in nucleoplasm, although its effect was milder
compared with full length Myeov2 (Fig. 3A and 3B). Because
Myeov2 was present in nucleoplasm but not nucleolus (Fig. 3A
and 3D), these data imply that expression of Myeov2 retains L11
in nucleoplasm. To next explore the mechanisms by which
Myeov2 controls L11 localization, we examined the interaction
between them. Myeov2 clearly bound to L11, and Myeov2DFD
was also capable of interaction even though its efficiency seems to
be weaker than full length (Fig. 3C). Therefore, it is likely that
Myeov2 induces suppression of Nedd8 modification through
interaction with L11, and segregates L11 from nucleolus. Because
L11 is released to nucleoplasm when nucleolus is disrupted
following nucleolar stress, we next asked whether expression of
Myeov2 induces nucleolar disruption. To examine this, we
transfected HeLa cells with EGFP-tagged nucleophosmin (NPM)
in the presence or absence of Myeov2 and observed the shape of
nucleolus using fluorescence microscope. When nucleolar stress
was induced by treatment with 10 nM Actinomycin D (ActD) for 4
hours, EGFP-NPM relocated to nucleoplasm. Myeov2 expression
did not induce changes of EGFP-NPM nucleolar localization,
indicating that overexpression of Myeov2 per se is not sufficient to
disrupt nucleolus. However, treatment with 10 nM ActD for
1 hour induced EGFP-NPM relocation in Myeov2-expressing
cells, but not control cells (Fig. 3D). Taken together, these data
indicate that an increase of Myeov2 expression level does not
trigger nucleolar disruption although Myeov2 makes nucleolus
vulnerable to stress. Presumably, Myeov2 causes defect in
nucleolar integrity by limiting L11 in nucleoplasm, and increases
sensitivity to a variety of stresses.
Expression of Myeov2 Induces an Increase of p53
Sensitivity
It has been reported that L11 stabilizes and activates p53 in
response to nucleolar stress [6,7,14]. Because p53 is considered to
be associated with multiple myeloma [24,25], and cells become
sensitive to nucleolar stress by expression of Myeov2 (Fig. 3D),
these observations prompted us to examine whether expression of
Myeov2 regulates p53 transcriptional activity. We first introduced
Myeov2 plasmids into HCT116 cells and measured p53
transcriptional activity using luciferase assay. Expression of
Myeov2 moderately increased p53 activity. In addition, this effect
was enhanced after treatment with 5 nM ActD (Fig. 4A). These
data are consistent with our notion that Myeov2 induces sensitivity
to nucleolar stress. We next investigated whether Myeov2 controls
p53 stability. A large amount of p53 disappeared about 1 hour
after treatment with 10 mM cycloheximide. The overexpression of
Myeov2 did not affect the p53 instability (Fig. 4B). In addition,
ubiquitination status of p53 did not change by expression of
Myeov2 (Fig. 4C), demonstrating that Myeov2 increases p53
transcriptional activity without affecting its ubiquitination nor
stability. To further confirm that Myeov2 does not control p53
ubiquitination, we asked whether Myeov2 is implicated in Mdm2
functions, which is a major ubiquitin ligase of p53. Consistent with
our data, expression of Myeov2 did not alter the ubiquitination
status of p53 even when Mdm2 was overexpressed (Fig. S4). In
addition, Myeov2 did not modulate the interactions of Mdm2 with
p53 and L11 (Fig. 4D), supporting the idea that Myeov2 has little
influence on the regulation of Mdm2 activity and p53 stability.
Taken together, these findings suggest that expression of Myeov2
is not correlated with the inhibition of p53 turnover, but is
sufficient to promote p53 activity moderately.
Discussion
Nedd8 modification pathway plays pivotal role in a wide variety
of cellular systems [32]. Recent studies have reported that
nucleolar stress is associated with tumorigenesis through regulation
of p53 pathway [1,2]. However, the mechanisms of how Nedd8
pathway is involved in this machinery remain elusive. Here, we
provide several lines of evidence that demonstrate Myeov2
regulates L11 subnucleolar localization that links nucleolar stress
to p53 pathway: (1) expression of Myeov2 leads to a global
decrease of neddylated proteins; (2) Myeov2 sustains L11 in a
lower neddylation status; (3) Knockdown of Myeov2 does not
enhance the neddylation level of L11; (4) Myeov2 alters the
subnuclear localization of L11; (5) the effect of Myeov2 is
independent of Nedd8 deconjugation enzymes, Nedp1 and
COP9 signalosome; (6) expression of Myeov2 induces an up-
regulation of p53 activity independent of p53 stability. These data
demonstrates that Myeov2 is not necessary to inhibit the basal
level of L11 neddylation. However, when expression level is
increased under abnormal condition, Myeov2 suppresses L11
neddylation through its interaction and segregates L11, allowing
an increase of stress sensitivity (Fig. 5). Thus, our findings provide
a clue that links Nedd8 pathway to pathogenesis of multiple
myeloma.
Nedd8 is a ubiquitin-like protein that conjugates to target
proteins and modulates its protein-protein interaction, subcellular
localization and enzymatic activity [33,34]. Since Nedd8 modifi-
cation is significantly involved in cellular proliferation, it is feasible
that abnormality in this pathway is associated with tumorigenesis
[32]. In fact, a chemical inhibitor MLN4924 that suppresses
Nedd8 E1 enzyme APPBP1/Uba3 inhibits cell cycle progression
[35]. Interestingly, MLN4924 is expected to be a potent
therapeutic agent for multiple myeloma and clinical trial is on
going. The mechanisms of how MLN4924 is effective for multiple
myeloma has not been understood, but our data provide a
tantalizing prospect that MLN4924 blocks neddylation of ribo-
Figure 2. Expression of Myeov2 maintains L11 in a lower neddylation level in cells. (A) HEK293 cells were transfected with HA-Nedd8 and
either Flag-Myeov2 or Flag-Myeov2DFD. Cell lysates were subjected to immunoblot analysis using indicated antibodies. (B) HEK293T cells were
transfected with either Flag-Myeov2 or Flag- Myeov2DFD and then treated with 10 mM MG132 for 1 hour prior to harvest. Cell lysates were subjected
to immunoblot analyses. Arrowhead indicates putative Myeov2 target protein. (C, D and E) HEK293T cells were transfected as indicated. Neddylated
proteins were precipitated from denatured cell lysates using Talon metal affinity resin and immunoblotted with indicated antibodies. Arrowheads
indicate neddylated L11.
doi:10.1371/journal.pone.0065285.g002
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somal protein such as L11, allowing vulnerability of nucleolus and
activation of p53 pathway.
p53 is one of well-characterized tumor suppressor proteins,
which is normally ubiquitinated by Mdm2. So far, it has been
reported that several ribosomal proteins are released from
nucleolus in response to nucleolar stress and suppress Mdm2
activity, followed by activation of p53 pathway. Although we
found that overexpression of Myeov2 retains L11 in nucleoplasm
and increases p53 transcriptional activity, the rate of increase in
transcriptional activity appears not to be forceful. Because we
found that Myeov2 is not sufficient to induce nucleolar disruption,
it is possible that the release of other ribosomal proteins caused by
nucleolar stress is required for substantial activation of p53. This
idea is consistent with our data that Myeov2 did not affect
Figure 3. Myeov2 alters L11 subnuclear localization without nucleolar disruption. (A) HeLa cells were transfected with Myc-L11, together
with either Flag-Myeov2 or Flag- Myeov2DFD plasmids, and subjected to immunocytochemistry. Arrows and arrowheads indicate Myeov2-expressing
and control cells, respectively. Scale bar, 20 mm. (B) Quantification of the data in (A). Subnuclear localization of Myc-L11 in Flag-Myeov2-positive cells
was examined. Cells that express L11 in nucleous only (yellow), both in nucleolus and nucleoplasm (blue) and nucleoplasm only (pink), were counted.
N denotes the number of cells counted. (C) Co-immunoprecipitation of Flag-Myeov2 or Flag-Myeov2DFD with HA-L11 in HEK293T cells. Cell lysates
were immunprecipiated with anti-Flag antibodies and analyzed using both Flag and HA antibodies. (D) HeLa cells transfected with EGFP-NPM and
HA-Myeov2 were treated with 10 nM ActD for indicated time, and subjected to immunocytochemistry. Expression of Myeov2 did not induce
nucleolar disruption in the absence of ActD (top panels). Nuclear disruption was observed in Myeov2-expressing cells at 1 hr of ActD treatment
(middle panels). 4 hrs of ActD treatment resulted in nucleolar disruption irrespective of Myeov2 expression (lower panels). Scale bar, 20 mm.
doi:10.1371/journal.pone.0065285.g003
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Figure 4. Expression of Myeov2 augments p53 activity independently of ubiquitination. (A) HCT116 cells were transfected with either
Myeov2 or empty vector, together with p53-promoter-luc plasmids, and were then stimulated with or without 5 nM ActD for 6 hours. p53 promoter
activity was analyzed by luciferase assay (n = 3, mean6SEM, * p,0.05 by one-way ANOVA). (B) HEK293 cells were transfected with Flag-Myeov2 and
were then treated with 10 mM cycloheximide for indicated times. Cell lysates were subjected to immunoblot analyses using anti-p53 and anti-Flag
antibodies. (C) HEK293T cells were transfected with indicated plasmids. Ubiquitinated proteins were precipitated from denatured cell lysates using
Talon metal affinity resin and immunoblotted with anti-His, anti-Flag, and anti-p53 antibodies. (D) Co-immunoprecipitation of HA-L11, HA-Myeov2
and endogenous p53 with Flag-Mdm2 in HEK293T cells. Cell lysates were immunoprecipitated with anti-Flag antibody and analyzed using Flag, HA,
Mdm2 and p53 antibodies. Asterisks indicate non-specific bands.
doi:10.1371/journal.pone.0065285.g004
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stabilization or ubiquitination of p53 (Fig. 4C). However, precise
mechanisms by which Myeov2 augments p53 pathway through
regulation of L11 localization remain an issue for future studies.
Myeov2 led to a global decrease of neddylated proteins
including ribosomal protein, L11. Of special note is that we did
not observe the enhancement of deneddylating activity of COP9
although Myeov2 associates with COP9 signalosome. COP9
signalosome was originally identified as a negative regulator that
control photomorphogenesis in plant [36]. Genetic analysis has
revealed that mutations in CSN genes exhibit seeding lethal and
abnormal light response, demonstrating that COP9 signalosome is
essential for a viability of plants [37]. Intriguingly, plant Myeov2
homolog, Smap1 and Smap2, have genetic and physical interac-
tions with a subset of COP9 subunits. An ectopic expression of
Smap1 partially compensated the morphological defect of CSN5a
mutant in plants, although Smap1 does not deconjugate Nedd8
from Cul1 [38,39,40]. This observation is consistent with our data
that expression of Myeov2 did not enhance the activity of COP9
signalosome, despite of its interaction (Fig. 1). Meanwhile, COP9
signalosome is associated with embryogenesis, stress response,
cellular proliferation and differentiation in mammals [41,42,43].
In particular, COP9 signalosome is linked to cell cycle regulation
and tumorigenesis. For instance, COP9 subunits such as CSN5
and CSN6 are excessively expressed in cancer cells such as
myeloma, leukemia and glioblastoma, and CSN5 is associated
with tumor suppressor genes such as p16, p27, p53 and Smad7
[42,43,44]. Furthermore, myeloid leukemia factor 1 (MLF1), a
novel binding partner of CSN3 that attenuates the ubiquitin ligase
activity of COP1, is capable of ubiquitinating p53 [45]. Of note is
that chromosomal translocation produces a fusion protein of
Figure 5. Model for the role of Myeov2 in nucleus. (A) Most of L11 is neddylated and localized in nucleolus. In response to nucleolar stress, L11
is deneddylated and relocates to nucleoplasm, leading to activation of p53. (B) Myeov2 blocks L11 neddylation by their interaction and suppresses
translocation of L11 into nucleolus, and make cells sensitive to stresses.
doi:10.1371/journal.pone.0065285.g005
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MLF1 with NPM, and is significantly associated with myelodys-
plastic syndoromes (MDS), followed by myeloid leukemia [46]. We
also found that Myeov2 interacts with COP9 signalosome and
activates p53. Since Myeov2 make nucleolus vulnerable to stress
stimulation, one potential hypothesis is that Myeov2-COP9
signalosome complex is required for maintenance of nucleolus or
p53 activity independently of deneddylation activity. However,
understanding the link between Myeov2 and COP9 signalosome
will be an important challenge for future experiments.
In addition to a set of CSN subfamily, we also identified other
intriguing proteins that co-precipitated with Myeov2, some of
them associated with cancer. It has been demonstrated that
elevation of calcium in blood is a typical feature of multiple
myeloma, and an abnormal calcium influx from extracellular
environment is involved in viability of myeloma cells [47]. In this
study, we found that Myeov2 binds to calmodulin and its
subfamily, calmodulin-like protein 3 (Fig. 1A). Calmodulin is a
well-characterized mediator that connects calcium ion to intra-
cellular signaling pathway. Thus, Myeov2 may regulate intracel-
lular calcium signaling through binding to calmodulin, and
determine cell fate such as proliferation and transformation.
Two other Myeov2 targets, Elongin-B and Elongin-C are
components of CRLs that is composed of Cul2, Elongin-B/
Elongn-C complex, and von Hippel-Lindau tumor suppressor
protein (pVHL). Mutation in VHL gene is associated with Von
Hippel-Lindau disease, which exhibits severe malignant tumors.
Thus, it is likely that Myeov2 also regulates Cul2-type CRLs and
its perturbation may cause several cancers. In fact, pVHL
increases p53 transcriptional activity mediated by promotion of
the binding between p53 and p300 [48]. We found that Myeov2
promotes p53 activity independent of ubiquitination or stabiliza-
tion of p53. Therefore, Myeov2 may mediate acetylation or
phosphorylation of p53, which lead to p53 transcriptional activity
in concert with Cul2-type CRLs.
In summary, we provide strong evidence that a novel multiple
myeloma-related protein, Myeov2, regulates Nedd8 modification
and nucleolar integrity. These findings reveal an unsuspected
function for Myeov2 that regulates L11, leading to regulation of
p53 stress response pathway. Therefore, it is possible that an
increase of Myeov2 expression level may suppress transformation
from plasma cells into plasmacytoma by promotion of p53
sensitivity. Taken together, our study suggests a rationale for
investigating Myeov2-dependent Nedd8 modification associated
with multiple myeloma.
Materials and Methods
Materials and Antibodies
Actinomycin D (SIGMA), Talon metal affinity resin (Clontech),
MG132 (Peptide Institute), Cyclohexamide (WAKO), and
Hoechst 33342 (Life Technologies) were purchased.
Antibodies to Flag (M2, SIGMA), Myc (9E10 Santa Cruz), HA
(A190-108A, Bethyl Lab., Inc), HA (Y-11, Santa Cruz), CSN5 (42,
BD Transduction Lab.), Cul1 (19/CUL-1, BD Transduction
Lab.), Tubulin (DM1A, SIGMA), His (GE Healthcare), p53 (DO-
1, Santa Cruz), and Mdm2 (N-20, Santa Cruz) were used for
immunoblot analyses. Antibodies to Myc (9E10, Santa Cruz), HA
(3F10, Roche), GFP (ab13970, abcam), and DYKDDDDK-tag
(#5407, Cell Signaling Technology) were used for immunocyto-
chemistry and Anti-Flag M2-agarose bead (SIGMA) for immuno-
precipitation. Antibody to Cul3 has been described previously
[49]. Anti-Nedd8 antiserum was raised by immunizing rabbit with
recombinant Nedd8.
Cell Culture and Transfection
HEK293 [50], HEK293T [51], HeLa [52], HCT116 [52] cells
were cultured in Dulbecco’s modified Minimal Essential Medium
(WAKO) containing 5–10% fetal bovine serum, penicillin (100
units) and streptomycin (100 mg) (P/S). Cells were transfected
with plasmids using Lipofectamine 2000 (Invitrogen), FuGENE
(Roche) or Polyethyleneimine (Polyscience, Inc.) according to the
manufacturer’s instructions.
Plasmid Construction
pCAGEN-His-Ub, pCAGEN-His-Nedd8, pCAGEN-Bla-HA-
Nedp1, PG13-luc, pcDNA3-Flag-Mdm2 constructs were provided
by Y. Gotoh (University of Tokyo, Japan) [53]. pEGFP-NPM1
was provided by J. Yanagisawa (University of Tsukuba, Japan).
Myeov2 was amplified from human cDNA (NIH Mammalian
Gene Collection, Clone ID 100014446, Invitrogen) and subcloned
into the BamHI and XhoI sites of pcDNA3-Flag. L11 was
amplified from 293 cells cDNA library and subcloned into the
BamHI site of pCS4-Myc and pCS4-HA. Deletion mutants of
Myeov2 was amplified from pcDNA3-Flag-Myeov2 and sub-
cloned into the BamHI and XhoI sites of pcDNA3-Flag. The
primers used for deletion mutants of Myeov2 were as follows:
Myeov2 forward, 59-AAAAGGATCCACATGTGGCGCG-
CGCCGGAAGC-39; and reverse, 59-AAAAAACTCGAGC-
TACCTCACATCTATGCATG-39. Myeov2DC forward, 59-
AAAAGGATCCACATGTGGCGCGCGCCGGAAGC-39; and
reverse, 59-AAAAAACTCGAGCTAATGTCATCATCATCAA-
AAAGATCTTCAAAA-39.
Myeov2DN forward, 59-GGATCCACATGGTTCCCGCAC-
TGCAGCGAGGGCAGTCG-39; and reverse, 59-AAAAAACT-
CGAGCTACCTCACATCTATGCATG-39. Myeov2DFD for-
ward, 59-AAAGGATCCACATGTGGCGCGCGCCGGAAGC;
Myeov2DFD reverse 59-ATGGACTTGGCAGCCAGCTCAG-
GACTGCC-39.
For the shMyeov2 contructs, the oligonucleotides corresponding
to the target sequence for Myeov2 (#1 59-CACAGGACGCT-
TAAGAAACA-39, #2 59-GGACGCTTAAGAAACAGTTTA)
were subcloned into pMXII vector.
Immunoblot Analysis
Cells were lysed in extraction buffer (0.5% NP-40, 20 mM Tris-
HCl (pH 7.5), 150 mM NaCl, 1 mM, EDTA, 1 mM DTT) and
centrifuged at 14,000 rpm for 5 minutes. The cleared lysates were
separated by SDS-PAGE, transferred to PVDF membrane,
probed with primary antibodies, and detected with HRP-
conjugated secondary antibodies and chemiluminescence reagent
(Amersham ECL Plus Western Blotting Detection Reagents, GE
Healthcare).
Immunoprecipitation
The cell lysates (see immunoblot analysis) was rotated with
anti-Flag agarose beads (SIGMA) or anti-HA agarose beads
(SIGMA) for 4 hours at 4uC. The immunoprecipitants were
washed and subjected to immunoblot analyses with indicated
antibodies.
His-tagged Pull down Assay
Cells were transfected with the indicated constructs and lysed in
extraction buffer (6 M guanidinium-HCl, 50 mM sodium phos-
phate buffer (pH 8.0), 300 mM NaCl and 5 mM imidazole). Cell
lysates were sonicated briefly and were then incubated with Talon
metal affinity resin (Clontech) for 4 hours at 4 Cu. The precipitants
were washed by buffer (50 mM sodium phosphate buffer (pH 8.0),
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300 mM NaCl and 5 mM imidazole) and were then subjected to
immunoblot anaylsis.
Immunocytochemistry
HeLa cells plated on 15 mm coverslips and grown in 12-well
plates were fixed with 4% paraformaldehyde in phosphate
buffered saline (PBS) for 10 minutes at room temperature. The
coverslips were washed in PBS, blocked with 5% bovine serum
albumin (BSA), and 0.4% Triton X-100 in PBS, then incubated
with the indicated primary antibodies for one hour at room
temperature or overnight at 4uC. Following PBS washes, samples
were incubated with secondary antibodies (Alexa Fluor 594 anti-
mouse IgG (1:500), Alexa Fluor 488 anti-rat IgG (1:500) and
Alexa Fluor 488 anti-chicken IgG (1:500)) for 30 minutes at room
temperature in blocking solution. Cells were imaged using a
fluorescence microscope (Keyence, BIOREVO BZ-9000). Fluo-
rescence images were analyzed using Image J.
Luciferase Assay
HCT116 cells were transfected with the PG13-Luc reporter
plasmid, which contains the firefly luciferase gene driven by p53
promoter, and a renilla luciferase expression plasmid as an internal
control. Cell lysates were subsequently assayed for both firefly and
renilla luciferase activities with Dual-Luciferase Reporter Assay
System (Promega), and the former activity was normalized on the
basis of the latter.
Supporting Information
Figure S1 Characterization of anti-Nedd8 antiserum. (A
and B) Immunoprecipitation of neddylated proteins. Neddylated
proteins were immunprecipiated from HEK293 cells using anti-
Nedd8 antiserum and analyzed with anti-Nedd8 antiserum (A)
and anti-Ub antibody (FK2, MBL).
(TIF)
Figure S2 Knockdown of Myeov2 has little effect on L11
neddylation. (A) HEK293 cells were transfected with expression
vectors encoding Flag-Myeov2 and Myeov2 shRNA. Cell lysates
were subjected to immunoblot anayses with antibodies to Flag,
GFP and Tubulin. The GFP loading control is expressed from the
same plasmid as the shRNA. Asterisk indicates non-specific bands.
(B) HEK293T cells were transfected with indicated plasmids.
Neddylated proteins were pulled down from denatured cell lysates
using Talon metal affinity beads, and analyzed by immunoblot
analyses using antibodies to His and Myc.
(TIF)
Figure S3 Myeov2 does not interact with Nedp1. (A and
B) Co-immunoprecipitation experiment of HA-Nedp1 and Flag-
Myeov2. HEK293T cells were co-transfected with HA-Nedp1 and
either Flag-Myeov2 or Flag-Myeov2DFD. Cell lysates were
immunprecipiated with either anti-HA or anti-Flag antibodies
and analyzed using Flag and HA antibodies.
(TIF)
Figure S4 Myeov2 does not alter Mdm2-mediated p53
ubiquitination. (A) HEK293T cells were transfected with
indicated plasmids. Ubiquitinated proteins were pulled down
from denatured cell lysates using Talon metal affinity beads, and
analyzed by immunoblot analyses using antibodies to His, HA,
p53 and Mdm2.
(TIF)
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